Prostate Cancer | Specialty

MFS: A New Endpoint for Nonmetastatic CRPC

December 28th 2017

Nonmetastatic CRPC: Considerations for Apalutamide

December 28th 2017

Apalutamide: A Next-Gen Agent for Nonmetastatic CRPC

December 28th 2017

The Value of AR-Targeted Therapy in CRPC

December 28th 2017

Approaching the Treatment of Nonmetastatic CRPC

December 28th 2017

Understanding Nonmetastatic CRPC: An Overview

December 28th 2017

Dr. Agarwal on Androgen Receptor Inhibitors for Prostate Cancer

December 27th 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses androgen receptor (AR) inhibitors for patients with prostate cancer.

Dr. Graff on the Role of Checkpoint Inhibitors in Prostate Cancer

December 27th 2017

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the role of checkpoint inhibitors and PARP inhibitors for patients with prostate cancer.

Role of PARP Inhibitors Developing in mCRPC

December 26th 2017

Alicia Morgan, MD, discusses the role of PARP inhibitors as a novel treatment strategy for patients with metastatic castration-resistant prostate cancer.

FDA Grants Apalutamide Priority Review for Nonmetastatic CRPC

December 21st 2017

The FDA has granted a priority review to a new drug application for apalutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Morgan on Olaparib for Metastatic Castration-Resistant Prostate Cancer

December 21st 2017

Alicia Morgan, MD, Mather Hospital, discusses the role of olaparib (Lynparza) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Immunotherapy Continues Growth With Trials in mCRPC

December 18th 2017

Julie Graff, MD, comments on the state of immunotherapy in mCRPC and some ongoing research in the field.

Dr. Oh on the Use of Abiraterone and Docetaxel in mCRPC

December 16th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the use of abiraterone acetate (Zytiga) and docetaxel (Taxotere) in patients with metastatic castration-resistant prostate cancer.

Dr. Oh Discusses Choosing Abiraterone in Prostate Cancer

December 14th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, explains when he would choose abiraterone acetate (Zytiga) for patients with prostate cancer.

Radium-223 Well Tolerated in Long-Term Safety Results in mCRPC

December 14th 2017

Three-year safety results from the ALSYMPCA trial showed that treatment with radium-223 dichloride (Xofigo) for men with mCRPC and symptomatic bone metastases was associated with minimal nonhematologic AEs.

Treatment Underuse in Prostate Cancer Rare, Disproportionately Affects Black Men

December 14th 2017

An analysis of racial disparities in prostate cancer treatment found that treatment underuse is rare, but when it does occur, it is almost exclusively in black men.

A Practice Model Designed to Reward Physician Partners Equally

December 14th 2017

Associated Medical Professionals of New York, a urology and radiation oncology practice, seeks to give its physician partners an equal share of its financial success while rewarding all staff members according to their levels of responsibility and workflow intensity.

Dr. Sweeney on Chemotherapy Versus Abiraterone for mCRPC

December 14th 2017

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the role of chemotherapy versus abiraterone (Zytiga) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Active Surveillance Underused in Prostate Cancer Patients Who Want to Preserve Sexual Function

December 13th 2017

In results from the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study, 52.6% said that preserving sexual function was “very important,” but only 43.4% were assigned to active surveillance.

Dr. Graff Discusses Sipuleucel-T in Patients With mCRPC

December 8th 2017

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses sipuleucel-T (Provenge) in patients with metastatic castration-resistant prostate cancer.